Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Potential Risk of Narcolepsy for Belsomra Should Be Thoroughly Communicated: Chuikyo
November 21, 2014
- Don’t Use Long-Listed Drugs, Dispense Generics: LDP Project Team
November 21, 2014
- Chuikyo OKs NHI Price Listing of 14 APIs/15 Products
November 20, 2014
- MHLW Will Rack Its Brain about How to Eke Out Social Security Funds: Shiozaki
November 20, 2014
- 3 Straight Years of NHI Price Cuts Loom as Abe Delays Sales Tax Hike, Eyes Now Turned to 2019 and Beyond
November 19, 2014
- MHLW OKs 4 Products Including New Indication for Spiriva
November 19, 2014
- Health Ministry Drug Evaluation Head Calls for Mulling Necessity of PI Studies for Japanese Patients
November 18, 2014
- Only Advantage of Authorized Generics is that “They Can Be Sold Earlier”: Prof. Ogata
November 18, 2014
- PAFSC 2nd Committee to Discuss Novartis’s Secukinumab on Nov. 28
November 18, 2014
- Editor’s Pick: Five Healthcare News Headlines for Nov. 4 - 14
November 17, 2014
- MHLW Official Says Penalty Rule Needs Review, Frowns on Sanguine Outlook for Annual Drug Price Cut
November 17, 2014
- PMDA to Accept All Requests for Generic Drug Face-to-Face Consultations
November 17, 2014
- MHLW to Report Poteligeo’s Additional Indication of Untreated CCR4-Positive ATL to PAFSC 2nd Committee on Nov. 28
November 17, 2014
- PMDA Looks to New Pre-Application Meetings to Shed Review Time
November 14, 2014
- New Japan NIH Head Asks Pharma Industry to Suggest Ideas for Benefit of Japanese People
November 13, 2014
- PMDA to Expand Consultation Services for Clinical Trials Initiated by Academia
November 12, 2014
- Blue, Yellow Letters to Cover Regenerative Medicines
November 11, 2014
- MHLW Mulls Creating Rules under Law for Patient-Initiated Mixed-Care System
November 11, 2014
- PAFSC First Committee to Discuss Takeda’s Vonoprazan on Nov. 21
November 11, 2014
- US FDA Withdraws Tentative Approvals for 2 Generic Drugs of Ranbaxy
November 11, 2014
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…